Key Highlights
- Circle Pharma raises $90 million in Series D funding led by The Column Group.
- Funding to support clinical trials of CID-078 and expand the company’s innovative pipeline.
- Backed by Nextech Invest, Euclidean Capital, and other investors.
- Circle Pharma’s MXMO macrocycle platform enables the development of cell-permeable therapies.
Source: Business Wire
Notable Quote
- “This financing not only enables us to progress CID-078 through critical stages of clinical development but also allows us to further advance our pipeline of innovative therapies targeting cancer and other serious diseases.” — David Earp, JD, Ph.D., CEO at Circle Pharma
SoHC's Take
This significant $90 million Series D funding positions Circle Pharma at the forefront of cancer therapeutics. With its MXMO macrocycle platform and a strong focus on cyclin-targeted therapies, Circle Pharma is tackling some of the most challenging targets in oncology. The continued support from investors like The Column Group underscores the confidence in their approach, which could lead to groundbreaking treatments for cancer and other serious illnesses. Circle Pharma’s progress with CID-078 could pave the way for new standards in cancer care, particularly in areas where current treatments have failed to meet clinical needs.
